Other languages Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
37.57 ^USD	+2.79%		+0.78%	-25.74%

May. 31	Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema	MT
May. 31	Transcript : Ionis Pharmaceuticals, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ionis Pharmaceuticals : Donidalorsen Ph3 Data EAACI'24 Webcast Slides	May. 31
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema	May. 31
Transcript : Ionis Pharmaceuticals, Inc. - Special Call	May. 31
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema	May. 31
Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema	May. 31
Ionis to hold donidalorsen Phase 3 data webcast	May. 28
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)	May. 23
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	May. 16
Sector Update: Health Care Stocks Ease Thursday Afternoon	May. 16
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High	May. 16
Sector Update: Health Care	May. 16
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness	May. 16
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study	May. 16
Stocks in motion: Walmart, Chubb, Deere...	May. 16
Sector Update: Health Care Stocks Steady Premarket Thursday	May. 16
Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results	May. 16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis	May. 16
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome	May. 16
Ionis to host 2024 virtual Annual Meeting of Stockholders	May. 15
Transcript : Ionis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM	May. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Other languages

Filters